For example, gene editing techniques, such as exon skipping, have demonstrated potential in conditions such as Duchenne muscular dystrophy (DMD), in which mutations in the dystrophin gene result in the lack of the dystrophin protein [80,81]. This evidence concerns the gene DMD and Duchenne muscular dystrophy.